Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 6/20 | 0.49 |
| ▸ | DRD2 | P14416 | 5/20 | 0.46 |
| ▸ | DRD3 | P35462 | 5/20 | 0.46 |
| ▸ | HTR2A | P28223 | 4/20 | 0.46 |
| ▸ | DRD1 | P21728 | 2/20 | 0.46 |
| ▸ | DRD5 | P21918 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.46 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13532700 | 0.88 | SIGMAR1 (0.53) | HTR1ADRD2CYP1A2 | |
| SCHEMBL8419573 | 0.82 | HTR1A (0.53) | HTR1ADRD2DRD3HTR2ADRD1 | |
| SCHEMBL8416456 | 0.81 | HTR1A (0.52) | HTR1ADRD2DRD3HTR2ADRD1 | |
| Lesopitron SCHEMBL246589 | 0.81 | HTR1A (0.52) | HTR1ADRD2DRD3HTR2ADRD1 | |
| SCHEMBL8417620 | 0.81 | HTR1A (0.54) | HTR1ADRD2DRD3HTR2ADRD1 | |
| SCHEMBL8416310 | 0.81 | HTR1A (0.59) | HTR1ADRD2DRD3HTR2ADRD1 | |
| Lesopitron SCHEMBL9201343 | 0.80 | HTR1A (0.51) | HTR1ADRD2DRD3HTR2ADRD1 | |
| Lesopitron SCHEMBL1822413 | 0.80 | HTR1A (0.51) | HTR1ADRD2DRD3HTR2ADRD1 | |
| SCHEMBL13532665 | 0.78 | HTR1A (0.52) | HTR1ADRD2DRD3HTR2ADRD1 | |
| SCHEMBL8416495 | 0.78 | HTR1A (0.55) | HTR1ADRD2DRD3HTR2ADRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0655248-B1 | Use of 1-4-4-aryl(or heteroaryl)-1-piperazinylbutyl-1H-azole derivatives for the preparation of medicaments for the treatment of disorders of gastric secretion | ESTEVE LABOR DR (ES) | 1999-09-15 | — | — | EP | claimed |
| US-5532234-A | Use of 1-[4-[4-aryl (or heteroaryl)-1-piperazinyl]-butyl)-1H-azole derivatives for the preparation of medicaments intended for the treatment of disorders of gastric secretion | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 1996-07-02 | — | — | US | claimed |
| EP-0502786-B1 | Process for the preparation of aryl(or heteroaryl)-piperazin-1-butyl-azole derivatives | ESTEVE LABOR DR (ES) | 1996-04-24 | — | — | EP | claimed |
| EP-0655248-A1 | Use of 1-4-4-aryl(or heteroaryl)-1-piperazinylbutyl-1H-azole derivatives for the preparation of medicaments for the treatment of disorders of gastric secretion | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 1995-05-31 | — | — | EP | claimed |
| EP-0429360-B1 | INHIBITION OF WITHDRAWAL SYNDROME | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 1993-10-13 | — | — | EP | claimed |
| EP-0502786-A1 | Process for the preparation of aryl(or heteroaryl)-piperazin-1-butyl-azole derivatives | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 1992-09-09 | — | — | EP | claimed |
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | BRAINCELLS, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | BRAINCELLS, INC. (US) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | HTR6, GAP43, HTR5A | HTR1A 7/4885DRD2 242/4885DRD3 432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.